Gross booking revenue in Q3 FY25 was ₹2,148.9 crore, indicating demand in the travel sector remained strong.
EBITDA was up 14.8% and stood at ₹635 crore compared to ₹553.2 crore, indicating improved operational performance.
Revenue fell by 2.6% year-on-year to ₹4,567.4 crore against ₹4,689.3 crore in Q3 FY24, indicating a marginal slowdown in business activity.
Following an inspection carried out from Nov 14-22 2024, the facility was cited as being ‘VAI’ (Voluntary Action Indicated).
In Q3 FY25, BHEL reported a 170% YoY increase in net profit, reaching ₹124 crore, while revenue grew 32% YoY to ₹7,277 crore, reflecting strong financial performance.
The company reported an 11.6% YoY de-growth in the same to ₹170 crore versus ₹192.2 crore in Q3 FY24.
Zydus Lifesciences announced it's Q3 FY25 and net profit grew by 30% YoY.
As part of the contract, debentures shall have a tenure of 3,651 days (approx. 10 years) and shall be listed on the Wholesale Debt Market
However, the company stated that its revenue from operations registered a growth of 66.90% to ₹534.70 Crore in Q3FY25.
The deal is aimed at improving operational efficiency, expanding capabilities, and fuel innovation in the maritime sector.

IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.